The short version of Melanotan II fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-22 and is reviewed periodically as new material appears.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
In multicellular organisms with dedicated reproductive cells, mutations can be subdivided into germline mutations, which can be passed on to descendants through their reproductive cells, and somatic mutations (also called acquired mutations), which involve cells outside the dedicated reproductive group and which are not usually transmitted to descendants. Diploid organisms (e.g., humans) contain two copies of each gene—a paternal and a maternal allele. Based on the occurrence of mutation on each chromosome, we may classify mutations into three types. A wild type or homozygous non-mutated organism is one in which neither allele is mutated.
==== Psychedelics, serotonin, and their actions ==== Serotonin, also known as 5-hydroxytryptamine (5-HT) and originally called enteramine, was discovered by Vittorio Erspamer in the 1930s and its structural identity was fully characterized in the late 1940s and early 1950s. Serotonin was discovered in the brain by Betty Twarog and Irvine Page in 1953. It was quickly noticed that LSD contains the serotonin-like tryptamine scaffold within its chemical structure. Shortly thereafter, it was found that LSD showed serotonin-like effects and could antagonize serotonin in certain assays. Studies in the 1960s and 1970s showed that various serotonin antagonists could block the behavioral effects of psychedelics in animals. It was first proposed that LSD may be acting as an agonist of serotonin receptors by N. E. Andén and colleagues in 1968. The serotonin receptors, including the serotonin 5-HT2 receptors, were identified by the late 1970s. Mediation of the hallucinogenic effects of psychedelics specifically by serotonin 5-HT2 receptor agonism was proposed by Richard Glennon and other researchers by the early 1980s. The human serotonin 5-HT2A receptor was first cloned in 1990. The hallucinogenic effects of psilocybin in humans were shown to be blocked by the selective serotonin 5-HT2A receptor antagonist ketanserin by Franz Vollenweider and colleagues in 1998, solidifying theoretical notions that agonism of the serotonin 5-HT2A receptor mediates the hallucinogenic effects of serotonergic psychedelics.
== Adverse events related to red blood cell transfusion == Adverse events related to transfusion in general may include allergic reactions such as anaphylaxis, infection, volume overload, and lung injury. With current screening methods, the risk of viral infections such as hepatitis C and HIV/AIDS are less than one in a million. With current testing methods in high-income countries the prevalence of transfusion-transmissible infections in blood donations is very low (median: HIV 0.002%, hepatitis B 0.02%, hepatitis C 0.007% and syphilis 0.02% in 2024). However, in low-income countries the risk of a blood donation being positive for HIV, hepatitis C or syphilis is up to 1%, and the risk of it being hepatitis B positive was approximately 2.8% in 2024. The differences relate to variations in eligible blood donors, whether the donation is paid or voluntary, non-remunerated, and the effectiveness of the system of educating and selecting donors. Adverse events related to transfusion of red blood cells are mainly linked to incompatibility issues or other transfusion reactions. Incompatible AB0 transfusion can be fatal. For patients with a previous transfusion reaction history, the risk of repeated adverse events can be mitigated by choosing the proper processing modification and/or red blood cell phenotype combination.
== Causes == Hyperglycemia may be caused by: diabetes, various (non-diabetic) endocrine disorders (insulin resistance and thyroid, adrenal, pancreatic, and pituitary disorders), sepsis and certain infections, intracranial diseases (e.g. encephalitis, brain tumors (especially if near the pituitary gland), brain haemorrhages, and meningitis) (frequently overlooked), convulsions, end-stage terminal disease, prolonged/major surgeries, stress, and excessive eating of carbohydrates.
==== Quaternary ammonium ==== The quaternary ammonium compound Dimethyloctadecyl (3-trimethoxysilyl propyl) ammonium chloride (Si-QAC) has been found to have antimicrobial activity when covalently bonded to a surface. Many other quaternary ammonium compounds are known to have antimicrobial properties (e.g. alkyldimethylbenzylammonium chloride and didecyldimethylammonium chloride). These last two are membrane-active compounds; against S. aureus the first forms a single monolayer coverage of the S. aureus cells on the outer membrane, while the second forms a double monolayer. This leads to cell leakage and total release of the intracellular potassium and 260 nm-absorbing pools in this order.
Sources: en.wikipedia.org
==== Dammaj clashes continue ==== The conflict in Dammaj was renewed in April when fighting broke out between Houthi tribesmen and Salafi students. Both sides accused the other of breaking a truce agreement.
== External links == Media related to Parathyroid hormone at Wikimedia Commons Parathyroid hormone: analyte monograph - the Association for Clinical Biochemistry and Laboratory Medicine Overview of all the structural information available in the PDB for UniProt: P01270 (Parathyroid hormone) at the PDBe-KB.
The persistence of apnea can depend on factors such as premedication, dose administered, and rate of administration, and may sometimes persist for longer than 60 seconds. Possibly as the result of depression of the central inspiratory drive, propofol may produce significant decreases in respiratory rate, minute volume, tidal volume, mean inspiratory flow rate, and functional residual capacity. Propofol administration also results in decreased cerebral blood flow, cerebral metabolic oxygen consumption, and intracranial pressure. In addition, propofol may decrease intraocular pressure by as much as 50% in patients with normal intraocular pressure. A more serious but rare side effect is dystonia. Mild myoclonic movements are common, as with other intravenous hypnotic agents. Propofol appears to be safe for use in porphyria, and has not been known to trigger malignant hyperthermia. Propofol is also reported to induce priapism in some individuals, and has been observed to suppress REM sleep and to worsen the poor sleep quality in some patients. Rare side effects include:
CH3CH=CH2 + H2 + CO → CH3CH2CH2CHO Butyraldehyde is converted on an industrial scale to 2-ethylhexanol, a precursor to PVC plasticizers, by aldol condensation, followed by hydrogenation of the resulting hydroxyaldehyde. The "oxo aldehydes" resulting from hydroformylation are used for large-scale synthesis of fatty alcohols, which are precursors to detergents. The hydroformylation is a reaction with high atom economy, especially if the reaction proceeds with high regioselectivity.
Sources: en.wikipedia.org
=== Acquisition of ZLB Bioplasma AG and Aventis Behring === In 2000, CSL doubled its size through the purchase of a Swiss plasma company, the Bern-based ZLB Bioplasma AG. In 2004, during a period of plasma oversupply, the company expanded again with the purchase of the German medical company Aventis Behring. The company was the second Australian public company to have reached a share price of over $100 per share.
Emergency locator beacon – a portable battery powered radio transmitter used in emergencies to locate airplanes, vessels, and persons in distress and in need of immediate rescue. Various types of emergency locator beacons are carried by aircraft, ships, vehicles, hikers and cross-country skiers. In the event of an emergency, such as the aircraft crashing, the ship sinking, or a hiker becoming lost, the transmitter is deployed and begins to transmit a continuous radio signal, which is used by search and rescue teams to quickly find the emergency and render aid. The latest generation Emergency Position Indicating Rescue Beacons (EPIRBs) contain a GPS receiver, and broadcast to rescue teams their exact location within 20 meters. Cospas-Sarsat – an international humanitarian consortium of governmental and private agencies which acts as a dispatcher for search and rescue operations. It operates a network of around 65 satellites carrying radio receivers, which detect distress signals from emergency locator beacons anywhere on Earth transmitting on the international Cospas distress frequency of 406 MHz. The satellites calculate the geographic location of the beacon within 2 km by measuring the Doppler frequency shift of the radio waves due to the relative motion of the transmitter and the satellite, and quickly transmit the information to the appropriate local first responder organizations, which perform the search and rescue.
With this model, journalists can instead focus on the positives of a story and ask questions about how conflicts or even tragedies have brought people together, how someone has experienced post-traumatic growth, and more. News stories then shift the perspective from a victimizing one to an uplifting one. Positive psychology is slowly but steadily making its way through news reporting via constructive journalism. PERMA helps journalists ask the right questions to continue that progress by bringing the focus of a potentially negative story to the positives and solutions.
Viola, commonly known as the violets, is a genus of flowering plants in the family Violaceae. It is the largest genus in the family, containing over 680 species. Most species are found in the temperate Northern Hemisphere; however, some are also found in widely divergent areas such as Hawaii, Australasia, and the Andes. Some Viola species are perennial plants, some are annual plants, and a few are small shrubs. Many species, varieties and cultivars are grown in gardens for their ornamental flowers. In horticulture, the term pansy is normally used for those multi-colored large-flowered cultivars which are raised annually or biennially from seed and used extensively in bedding.
=== Measuring antioxidant capacity === Cyclical voltammetry can be used to determine the antioxidant capacity in food and even skin. Low molecular weight antioxidants, molecules that prevent other molecules from being oxidized by acting as reducing agents, are important in living cells because they inhibit cell damage or death caused by oxidation reactions that produce radicals. Examples of antioxidants include flavonoids, whose antioxidant activity is greatly increased with more hydroxyl groups. The traditional method for evaluating antioxidant potential is via an assay, which is a time consuming process, possibly unrepresentative of a molecule's full antioxidant potential. Cyclic voltammetry addresses both issues, allowing faster experiment iteration, and more specific analysis. Furthermore, antioxidants are quickly oxidized at inert electrodes, so the half-wave potential can be utilized to determine antioxidant capacity. Whenever cyclic voltammetry is utilized, it is usually compared to spectrophotometry or high-performance liquid chromatography (HPLC). Applications of the technique extend to food chemistry, where it is used to determine the antioxidant activity of red wine, chocolate, and hops. Additionally, it even has uses in the world of medicine in that it can determine antioxidants in the skin.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.